Article Sidebar
Views PDF: 74
OUTCOME OF BEVACIZUMAB PLUS XELOX AS FIRST-LINE CHEMOTHERAPY FOR OVER 60 YEARS OLD PATIENTS WITH METASTATIC COLORECTAL CANCER
Main Article Content
Abstract
Objectives: to evaluate outcome of bevacizumab plus xelox as first-line chemotherapy for over 60 years old patients with metastatic colorectal cancer. Patients and Method: Descriptive, retrospective and prospective study. From January 2020 to October 2023, we enrolled 65 patients over 60 years old with metastatic colorectal cancer at K Hospital. All patients were used first-line chemotherapy with bevacizumab plus xelox regimens. Tumor response and progression free survival were determined. Results: Clinical features: The median of age was 67,1. The male/female ratio was 1,83. Rectal tumor is the most common site (46,2%). Moderately differentiated adenocarcinoma was the most common type with 86,2%. The time of first detection of the disease accounted for 62.5%. Results of treatment: The response rate was 56,9%, none of patient had complete response, partial response 56,9%, disease control rate was 80%; Median DFS time was 9,5 months. Conclusion: Bevacizumab plus xelox chemotherapy regimens is effective treatment and prolong survival for over 60 years old patients with metastatic colorectal cancer.
Article Details
References
2. https://www.esmo.org/guidelines/ guidelines-by-topic/gastrointestinal-cancers/metastatic-colorectal-cancer
3. https://www.nccn.org/professionals/ physician_gls/pdf/colon.pdf.
4. Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011;128(3):682-690. doi:10.1002/ijc.25369
5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12): 1539-1544. doi:10.1200/JCO.2006.09.6305
6. Gallego R, Sanchez N, Maurel J. Chemotherapy for elderly patients with advanced colorectal carcinoma. Expert Rev Anticancer Ther. 2006;6(5): 795-800. doi: 10.1586/14737140.6. 5.795
7. Yoshida M, Muro K, Tsuji A, et al. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer. 2015;51(8): 935-941. doi:10.1016/j.ejca. 2015.03.007
8. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077-1085.
9. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study - PubMed. Accessed February 28, 2023. https://pubmed. ncbi.nlm.nih.gov/24946000/
10. Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol. 2013;71(1):257-264.